ConductScience.org, home

Comparison · NCT05049616-f8d64686

Hctz/Lisinopril vs Extended release nifedipine: Postpartum Complications- Number of Participants With Maternal Death

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Hctz/Lisinopril vs Extended release nifedipine: Postpartum Complications- Number of Participants With Maternal Death. Trial comparisons, record NCT05049616-f8d64686. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05049616-f8d64686

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.11wilson
Risk in group 2000.0964wilson
Risk difference, group 1 minus group 20-0.09640.11newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Hctz/Lisinopril
Hctz/Lisinopril for postpartum management of hypertension. either a combined pill of ACE inhibitors and diuretics (Hydrochlorothiazide/Lisinopril)~ACE Inhibitors and Diuretics: Hctz/Lisinopril (brand name: Zestoretic)
031OG000
Group 2Extended release nifedipinecalcium channel blocker (Nifedipine~NIFEdipine ER: Extended release nifedipine036OG001

Outcome

Type
SECONDARY
Title
Postpartum Complications- Number of Participants With Maternal Death
Description
Maternal death
Time frame
10 days postpartum
Population

Source ClinicalTrials.gov

Trial

Title
Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension
NCT number
NCT05049616
Phases
PHASE4
Conditions
Hypertension in Pregnancy, Postpartum Preeclampsia
Interventions
ACE Inhibitors and Diuretics, NIFEdipine ER
Lead sponsor
The University of Texas Health Science Center, Houston
Results first posted
2023-08-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05049616-f8d64686